Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
06:45am, Thursday, 12'th Jun 2025
LAUSANNE, Switzerland , June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
06:30am, Thursday, 12'th Jun 2025
ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Monday, 02'nd Jun 2025
LAUSANNE, Switzerland , June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
ADC Therapeutics to Present at Upcoming Investor Conferences
07:15am, Thursday, 15'th May 2025
LAUSANNE, Switzerland , May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced par
ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript
12:36pm, Wednesday, 14'th May 2025
ADC Therapeutics SA (NYSE:ADCT ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Corporate Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Mohame
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
10:10am, Wednesday, 14'th May 2025
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.56 per share a year ago.
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
08:00am, Wednesday, 14'th May 2025
LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab
ZYNLONTA ® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL Safety and tolerability data were consistent with the k
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025
07:15am, Thursday, 08'th May 2025
LAUSANNE, Switzerland , May 8, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:06am, Monday, 28'th Apr 2025
ADC Therapeutics (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
07:00am, Monday, 28'th Apr 2025
Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer Poster presentations highlight antitumor activ
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment
09:47am, Friday, 11'th Apr 2025
The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Tuesday, 01'st Apr 2025
LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced t
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
07:15am, Tuesday, 01'st Apr 2025
LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Ne
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript
11:17am, Thursday, 27'th Mar 2025
ADC Therapeutics SA (NYSE:ADCT ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Pepe C
